Previous Mitral Valve Replacement
To assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing mitral bioprosthetic (tissue) valve who are an intermediate surgical risk.
Principal Investigators: Robert L. Smith, II, MD / Molly Szerlip, MD
Locations: Baylor Scott & White The Heart Hospital – Plano
IRB Number: 017-468
Trial Status: Enrolling
Exclusions: Adults only
Change in Care:
Necole Kell, RN469.814.4871Necole.Kell@BSWHealth.org
Brittany Zingler, RN469.814.4737Brittany.Zingler@BSWHealth.org
A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Requiring Aortic Valve Replacement who have Severe, Calcific, Symptomatic Aortic Stenosis
Get Detailed Information On Clinicaltrials.gov »
Physicians are members of the medical staff at one of Baylor Scott & White Health's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, Baylor Scott & White The Heart Hospital – Plano or Baylor Scott & White Health.